Meta-Analysis
doi: 10.1016/j.lungcan.2015.06.018.
Epub 2015 Jun 23.
Second line therapy in malignant pleural mesothelioma: A systematic review
Affiliations
- PMID: 26162564
- DOI: 10.1016/j.lungcan.2015.06.018
Item in Clipboard
Meta-Analysis
Second line therapy in malignant pleural mesothelioma: A systematic review
Lung Cancer.
2015 Sep.
Abstract
After the implementation of standard first line chemotherapy with platinum and antifolates in pleural mesothelioma, patients are confronted with a need for second line treatment at relapse or progression. We conducted a systematic review of the literature for the activity, effectiveness and toxicity of second line treatment. The results are presented according to the class of drugs: chemotherapy and targeted or biological agent.
Keywords: Biological; Chemotherapy; Mesothelioma; Meta-analysis; Outcome; Second line; Targeted treatment; Treatment.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Radical multimodality therapy for malignant pleural mesothelioma.Cochrane Database Syst Rev. 2018 Jan 8;1(1):CD012605. doi: 10.1002/14651858.CD012605.pub2. Cochrane Database Syst Rev. 2018. PMID: 29309720 Free PMC article.
-
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.Lung Cancer. 2014 Feb;83(2):240-5. doi: 10.1016/j.lungcan.2013.11.026. Epub 2013 Dec 6. Lung Cancer. 2014. PMID: 24360321
-
The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.Hum Pathol. 2017 Sep;67:160-168. doi: 10.1016/j.humpath.2017.07.015. Epub 2017 Aug 4. Hum Pathol. 2017. PMID: 28782639
-
Systematic review of pleurectomy in the treatment of malignant pleural mesothelioma.Lung Cancer. 2013 Sep;81(3):319-327. doi: 10.1016/j.lungcan.2013.04.024. Epub 2013 Jun 13. Lung Cancer. 2013. PMID: 23769317
-
Cytoreductive surgery with hyperthermic intrathoracic chemotherapy for malignant pleural mesothelioma: a systematic review.Thorax. 2023 Apr;78(4):409-417. doi: 10.1136/thoraxjnl-2021-218214. Epub 2022 Apr 11. Thorax. 2023. PMID: 35410957
Cited by
-
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study.Lancet Respir Med. 2021 Sep;9(9):969-976. doi: 10.1016/S2213-2600(21)00043-6. Epub 2021 Apr 9. Lancet Respir Med. 2021. PMID: 33844995 Free PMC article.
-
CSF1/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PDL1 Immunotherapy.Cancers (Basel). 2021 May 22;13(11):2546. doi: 10.3390/cancers13112546. Cancers (Basel). 2021. PMID: 34067348 Free PMC article.
-
Integrating data from multidisciplinary Management of Malignant Pleural Mesothelioma: a cohort study.BMC Cancer. 2021 Jul 1;21(1):762. doi: 10.1186/s12885-021-08532-x. BMC Cancer. 2021. PMID: 34210265 Free PMC article.
-
DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma.Int J Oncol. 2017 Jul;51(1):91-103. doi: 10.3892/ijo.2017.4021. Epub 2017 May 26. Int J Oncol. 2017. PMID: 28560410 Free PMC article.
-
MicroRNA-31 Regulates Chemosensitivity in Malignant Pleural Mesothelioma.Mol Ther Nucleic Acids. 2017 Sep 15;8:317-329. doi: 10.1016/j.omtn.2017.07.001. Epub 2017 Jul 8. Mol Ther Nucleic Acids. 2017. PMID: 28918032 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
